Karen Andersen, CFA

Title Collection Author Date
What Next in the Hunt for a Covid-19 Vaccine? Economic Insights Karen Andersen, CFA 04/09/20
What a Covid-19 Vaccine Means for Investors Equity Research & Insights Karen Andersen, CFA 21/07/20
Shire Stock Undervalued Despite Takeover Bid Equity Research & Insights Karen Andersen, CFA 20/04/18
Takeda Takeover Bid for Shire: Analyst View Equity Research & Insights Karen Andersen, CFA 29/03/18
Raising Our Fair Value Estimate for Shire Equity Research & Insights Karen Andersen, CFA 09/11/11
Astra's Diabetes Drug Hurdles May Aid Competitors Equity Research & Insights Karen Andersen, CFA 21/07/11
We're Suspending Shire's Credit Rating Equity Research & Insights Karen Andersen, CFA 19/05/11
Sanofi-Aventis Hasn't Got Genzyme in the Bag Yet Equity Research & Insights Karen Andersen, CFA 14/12/10
Genzyme's Rebound Will Weigh on Shire's Growth Equity Research & Insights Karen Andersen, CFA 01/11/10
Elan’s Alzheimer’s Drug Candidate Misses the Mark Equity Research & Insights Karen Andersen, CFA 11/08/10
Shire's Strong Growth to Moderate in Second Half Equity Research & Insights Karen Andersen, CFA 06/08/10
Shire Should Return to Growth in 2010 Equity Research & Insights Karen Andersen, CFA 07/06/10
Shire's Newer Products Balance Adderall Generics Equity Research & Insights Karen Andersen, CFA 30/04/10
Smooth 1Q for Roche Equity Research & Insights Karen Andersen, CFA 16/04/10
2008 Investing Do's and Don'ts Fund Research & Insights Karen Andersen, CFA 08/01/08
Page   1 of 1

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies